drugset / Trial / NCT01324570
Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to characterize the safety, PK, and efficacy of BTDS in patients of ages 7 to 16 years.
Timeline
- Start
- 2011-07
- Primary completion
- 2016-05
- Completion
- 2016-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buprenorphine | Other / unclassified | 2.5 ug | Other |
| Subject | Buprenorphine | Other / unclassified | 5 ug | Other |
| Subject | Buprenorphine | Other / unclassified | 10 ug | Other |
| Subject | Buprenorphine | Other / unclassified | 20 ug | Other |
Indications
No indication recorded.